title: Effects of androgen deprivation on chronic bacterial prostatitis in a rat model.
abstract: BACKGROUND
  Many attempts have been made to improve the treatment success rate of chronic bacterial prostatitis (CBP). However, no treatment modality has achieved complete cure. The growth and development of the prostate is under direct hormonal control, and it is possible that prostatitis may be directly influenced by its hormonal milieu in a similar fashion to benign prostatic hyperplasia and prostate cancer. Therefore, the effects of androgen deprivation on the treatment of CBP were investigated in rats.
  
  
  METHODS
  Experimental CBP was induced in one hundred, male Wistar rats by instillation of bacterial suspension (Escherichia coli Z17, O2: K1: H-) containing 1 x 10(8) CFU/ microL into the prostatic urethra. Microbiologically and histologically proven CBP was demonstrated in 62% (62 of 100) of the rats after 4 weeks of bacterial instillation. The 62 rats demonstrating CBP were randomly divided into five groups: control; castration; finasteride; estrogen; and levofloxacin groups. All drug treatments were conducted over a period of 4 weeks.
  
  
  RESULTS
  Microbiological cultures and histological findings of the prostate and urine samples demonstrated reduced bacterial growth and improved inflammatory responses in all four experimental groups compared with the control group. The castration and estrogen groups showed coherent trends of decrease in bacterial growth and improvements in prostatic inflammation compared with the control group, but not to a statistically significant degree (P > 0.05). However, the finasteride and levofloxacin groups did show statistically significant decreases in bacterial growth and improvements in prostatic inflammation compared with the control group (P < 0.05).
  
  
  CONCLUSIONS
  These results suggest that androgen deprivation is an effective modality in CBP treatment. In particular, the finasteride treatment reduced the severity of CBP in the animal model without reducing the systemic testosterone level. The combination of finasteride and levofloxacin maybe one of the effective treatment modalities for CBP.
authors.affiliation: Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Seong Il
authors.initials: SI
authors.lastname: Seo
authors.forename: Seung-Ju
authors.initials: SJ
authors.lastname: Lee
authors.forename: Joon Chul
authors.initials: JC
authors.lastname: Kim
authors.forename: Yeong-Jin
authors.initials: YJ
authors.lastname: Choi
authors.forename: Sae Woong
authors.initials: SW
authors.lastname: SW
authors.forename: Tae Kon
authors.initials: TK
authors.lastname: Hwang
authors.forename: Yong-Hyun
authors.initials: YH
authors.lastname: Cho
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000818:Animals; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use; D002369:Castration; D002908:Chronic Disease; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy* / Q000652:urine; D004958:Estradiol / Q000494:pharmacology; D004967:Estrogens / Q000097:blood; D018120:Finasteride / Q000494:pharmacology; D064704:Levofloxacin; D008297:Male; D023421:Models, Animal; D015242:Ofloxacin / Q000494:pharmacology; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013739:Testosterone / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D000892:Anti-Infective Agents, Urinary; D004791:Enzyme Inhibitors; D004967:Estrogens; D013739:Testosterone; D004958:Estradiol; D018120:Finasteride; D064704:Levofloxacin; D015242:Ofloxacin